Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Companion Protocol for the ¹³C-Methacetin Breath Test (MBT) for Use in Bristol-Myers Squibb Phase 2b Studies for BMS-986036 (PEG-FGF21), Under Studies Referenced in NCT03486899, NCT03486912

NCT03611101 is registered in ClinicalTrials.gov with Meridian Bioscience, Inc. as lead sponsor.

NCT NCT03611101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03611101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Companion Protocol for the ¹³C-Methacetin Breath Test (MBT) for Use in Bristol-Myers Squibb Phase 2b Studies for BMS-986036 (PEG-FGF21), Under Studies Referenced in NCT03486899, NCT03486912
Lead sponsor
Meridian Bioscience, Inc.
Phase
Not reported
Overall status
Completed
Start date
May 4, 2018
Completion date
November 10, 2021
Enrollment
124 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nash - nonalcoholic steatohepatitis